Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

To Estimate the Myocarditis or Pericarditis Events After BNT162b2 (Tozinameran) Vaccination in Individuals With Age Group 12 to 17 Years in Ontario, Canada: A population-based cohort study

Next Previous
Trial Profile

To Estimate the Myocarditis or Pericarditis Events After BNT162b2 (Tozinameran) Vaccination in Individuals With Age Group 12 to 17 Years in Ontario, Canada: A population-based cohort study

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Mar 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tozinameran (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions

Most Recent Events

  • 03 Mar 2023 New trial record
  • 27 Feb 2023 Results (N=77) assessing variation in the reported incidence of myocarditis or pericarditis after BNT162b2 vaccination among adolescent age groups (12-15 years and 16-17 years) , published in the JAMA Pediatrics.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top